Nicotine pouch ingestions among children have surged, new study finds
The study, published Monday in the journal Pediatrics, found reports of children under 6 years old ingesting nicotine pouches increased from less than 1 per 100,000 in 2020 to more than 4 per 100,000 in 2023 — a 763% increase.
Unlike smoking and vaping, nicotine pouches — like popular brand Zyn — are smoke- and tobacco-free, but the pouches still contain nicotine, an addictive chemical that can be fatally toxic to young children.
Researchers analyzed calls to U.S. poison centers from 2020, which is when these pouches were first tracked in national poison center data, to 2023, the most recent available data.
"Nicotine pouches are a serious and growing toxic ingestion hazard among young children," said Dr. Hannah Hays, co-author of the study and medical director of the Central Ohio Poison Center, said in a news release.
The study also looked at ingestions of other nicotine products and formulations, including cigarettes, chewing tobacco, e-cigarettes and liquids.
Overall, researchers examined nearly 135,000 cases of nicotine ingestions among young children in the U.S. from 2010 to 2023, finding most cases occurred at home and involved children under 2 years old.
From 2010 to 2015, the overall rate of all nicotine ingestions increased 59%, but then decreased 34% from 2015 to 2023, researchers found, making the sharp rise in pouch ingestions a concerning contrast.
While pouch ingestions only made up 1.4% of the cases examined in the study, they were more likely to be associated with serious medical outcomes or hospital admissions than ingestions of other products, according to the study.
"Many nicotine products are flavored and sold in colorful packaging that may be attractive to a young child," Dr. Gary Smith, senior author of the study and director of the Center for Injury Research and Policy at Nationwide Children's, said in the release. "Banning flavors in all nicotine products helps reduce unintentional ingestions by young children as well as discourage use among teens."
Earlier this year, the Food and Drug Administration authorized the parent company of Zyn's manufacturer to sell the product to help adult smokers cut back or quit cigarettes. The authorization included 10 Zyn flavors, including coffee, mint and menthol.
It was the first time regulators have authorized sales of nicotine pouches, which are the fastest-growing segment of the U.S. tobacco market, and prompted health advocates to criticize the FDA's decision.
Sen. Lindsey Graham says "a turning point, regarding Russia's invasion of Ukraine, is coming"
Student's unique talent that's for the birds
Candy Land, the game that still hits a sweet spot
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
WASHINGTON (AP) — U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. The Food and Drug Administration issued two alerts Wednesday about electrical problems tied to the company's heart-zapping defibrillator systems and a separate issue with a heart implant used to reduce stroke risk. The agency said the company's Endotak Reliance defibrillator wires can become calcified, leading to failures in delivering life-saving shocks to the heart, according to the FDA. Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal. As of July 24, Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said. Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants. Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure. In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke. In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke. As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said. A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system. Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter. Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Yahoo
12 minutes ago
- Yahoo
Miss Universe Canada contestant Sara Levitt hopes to be the first winner with Crohn's disease: 'A difference can be a superpower'
Model Sara Levitt is raising awareness for people with ostomy bags and chronic health issues. (Image courtesy of Sara Levitt/Yahoo Canada) Sara Levitt and her life-saving ostomy bag are front and centre at the 2025 Miss Universe Canada pageant. On Aug. 9, the 30-year-old model will compete against 70 other delegates while raising visibility for people living with Crohn's disease. It isn't the first time Levitt and her ostomy bag — a pouch attached to the abdomen that collects bodily waste — have received wide scale attention. The Montréal-born model has walked New York Fashion Week and appeared in Maxim Australia with her bag proudly on display. Yahoo Canada spoke to Levitt about living with a chronic illness, competing in Miss Universe Canada and more. 'I was fighting for my life' Levitt has been battling Inflammatory Bowel Disease (IBD) for the majority of her life. She was diagnosed with ulcerative colitis at the age of three, and by the time she turned 11, her condition had progressed to Crohn's Disease. The next two years were some of the 'most intense and challenging' of her life, filled with severe chronic pain and countless hospital stays. Advertisement 'I was fighting for my life,' she said. 'It was a really dark time and I felt completely alone and ashamed.' In 2008, at the age of 13, Levitt underwent an emergency surgery to have part of her bowel removed. She was left with a permanent ostomy bag, a device she wears on the outside of her body that collects her stool. Levitt was diagnosed with ulcerative colitis and Crohn's Disease as a child. (Image courtesy of Sara Levitt) Going into the surgery, Levitt wondered how she would adapt to living with an ostomy. She dreaded what it would be like to have to carry physical evidence of her illness on her body each day. Unfiltered conversations with the names you know: Unapologetically is a Yahoo Life series in which people get the chance to share how they live their best life — out loud and in colour. Every week, check back for a new feature. 'There was a piece of me that was hoping I'd wake up and the bag wouldn't be there,' she said. 'When I woke up, I took my right hand, slid it down my hospital gown, and there it was.' Liv-ing out loud Levitt is upbeat and positive about life with an ostomy, but she wasn't always this way. The first 15 years that followed her ostomy surgery were difficult and dark, and she dealt with her new life alone and with shame. She avoided wearing anything that would reveal her ostomy, she hid her bag from romantic partners and she lived in fear of other peoples' opinions. Advertisement For Levitt, the lack of representation for ostomates — people who have undergone ostomy surgery —contributed to her feeling alone. After years of suffering in silence, Levitt decided she'd had enough; she knew she deserved to live her life to the fullest just as much as anyone else. 'It got to the point where I was just so physically and mentally drained,' she said. 'In summer 2023, I had a bit of an epiphany and I was like, 'I feel really confident in who I am and I've been through a lot and I'm ready to just be me.'' At the time, her Instagram was a personal account for friends, family and acquaintances. But after posting the photos, comments and messages began to pour in from other people with chronic illnesses who wanted to express gratitude for what she had done. Advertisement The response showed Levitt how great the need was for advocacy and representation from ostomates, so she kept posting. Her community grew, and today she has 35,000 followers on Instagram, where she calls herself 'The Bag Bish.' Levitt has named her ostomy bag "Liv" which means "life" in Swedish. (Image courtesy Sara Levitt) She now wears her ostomy — which she named Liv ('life' in Swedish) — with pride, donning bikinis and dresses that intentionally show off the bag that saved her life. " It's all about me and Liv living our best lives and showing others not to fear ostomy life,' she said. "It's about showing people you can have dreams and having a difference can be a superpower.' She regularly receives messages from people who say she's inspired them to wear a certain outfit that reveals their ostomy or to partake in an experience they would've otherwise avoided, and she does her best to respond to as many as she can. It's about showing people you can have dreams and having a difference can be a superpower Sara Levitt 'To know that I have that ability to alter and change somebody's views and enable them to live their life completely and fully with a visible difference or a chronic illness has given me so much purpose in life,' she said. 'That alone is fuel to my motivation and every single thing that I do.' It's in the bag In May, Levitt announced she was participating in the Miss Universe Canada pageant this August. She'll be the first ostomate, and first woman with any visible difference to compete. In a post to Instagram, Levitt said her hope was to help show "other woman our challenges do not define us, but merely give us an additional source of strength, and that there is space for us all." Sara Levitt is the first woman with a visible difference and ostomy bag to compete in the Miss Universe Canada pageant. (Image courtesy of Sara Levitt) For her humanitarian project for the pageant, she's raising awareness and funds for the Canadian Mental Health Association, a cause she described as deeply personal to her journey. Her health issues s took a serious toll on Levitt's own mental health for many years, and she hopes to shine a light on how chronic illnesses impact every aspect of a person's life — including their mental health. Advertisement Research shows that psychiatric disorders are 1.5 to 2 times more prevalent in those with IBD than in the general population, and rates are even higher when considering standalone mental health symptoms, as nearly one-third of individuals with IBD experience elevated anxiety symptoms and one-quarter experience depression symptoms. 'Hopefully I'm able to inspire and touch someone through sharing my story,' she said. 'Just being on that stage and being able to show my community, 'Look where we can go, look what we can do,' it's like we've already got the crown.' Let us know what you think by commenting below and tweeting @YahooStyleCA! Follow us on Twitter and Instagram.
Yahoo
12 minutes ago
- Yahoo
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
BEDFORD, Mass., August 06, 2025--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 11:30 a.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at About Stoke TherapeuticsStoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit View source version on Contacts Stoke Media & Investor Contacts: Dawn KalmarChief Communications Officerdkalmar@ 781-303-8302 Doug SnowDirector, Communications & Investor RelationsIR@ 508-642-6485
